Discontinuation of disease modifying therapies is associated with ...

MS patients with stable disease course experience DWP after treatment discontinuation, with no clear relation to age and disease subtype.

Highlights. •. No guidelines regarding discontinuation of therapy in multiple sclerosis (MS). •. 32.9% previously stable MS patients have disability worsening ...

Discontinuation of disease modifying therapies is associated with ...

Results. From the cohort of 216 MS patients who discontinued DMT, 161 (72.5%) were classified as stable before DMT discontinuation. After DMT discontinuation, ...

Discontinuation of disease modifying therapies is associated with ...

Highlights. •. No guidelines regarding discontinuation of therapy in multiple sclerosis (MS). •. 32.9% previously stable MS patients have ...

Discontinuation of disease-modifying therapies in multiple sclerosis

Background: Stable disease course may prompt consideration of disease-modifying treatment (DMT) discontinuation in relapsing-remitting multiple sclerosis (RRMS) ...

Discontinuation of Disease Modifying Therapies in Stable MS ...

Discontinuation of Disease Modifying Therapies in Stable MS Patients is Associated with Disability Progression Regardless of Age. (S8.008).

Impact of discontinuing disease-modifying therapies on health care ...

This study revealed that DMT discontinuation was associated with higher health care services utilization among midlife patients with MS, ...

Disease-Modifying Therapy Discontinuation in Multiple Sclerosis

One of greatest benefits would be reduction of DMT-associated adverse events, including risk of both minor and serious infections. ... Discontinuation of Disease ...

Discontinuation of Disease Modifying Therapies is Associated with ...

Similarly, previous NYSMSC analysis did suggest that up to 32.9% of clinically stable pwMS start to experience new disability worsening after they discontinue ...

Discontinuing Disease-Modifying Therapies in Multiple Sclerosis

Some DMTs pose higher risks as disability accrues. For example, risk of infection in people with MS and related conditions who take rituximab is 8 times higher ...

Discontinuation of first-line disease-modifying therapy in relapse ...

Higher age at first-line DMT discontinuation is associated with lower risk and severity of radiological disease activity in MS, and a lower risk ...

Comparing Stopping or Continuing Use of Disease Modifying ...

Disease modifying therapies, or DMTs, are medicines that help prevent or reduce relapses among patients with MS. But many older patients with MS don't have ...

Disease Reactivation After Cessation of Disease-Modifying Therapy ...

Once the reason for treatment discontinuation passes, patients return to baseline levels of disease activity. As all relapses within 30 days constitute a single ...

Discontinuation of disease-modifying therapies and health ...

DMT discontinuation was also associated with higher rates of relapse-related hospitalizations and outpatient visits.Our research reveals a growing trend in DMT ...

Discontinuing disease-modifying multiple sclerosis therapies

despite similar relapse rates in those who continued and those who discontinued such treatment, the hazard of disability progression was increased for patients ...

Insufficient Evidence to Suggest Discontinuation of MS Disease ...

Insufficient Evidence to Suggest Discontinuation of MS Disease-Modifying Therapies Leads to Worsened Patient-Reported Outcomes ... After a median ...

Treatment Discontinuation and Disease Progression with Injectable ...

Injectable first-line disease-modifying therapies (DMTs) for multiple sclerosis (MS) are generally prescribed for continuous use.

For Older Patients With Multiple Sclerosis, Discontinuing Disease ...

Discontinuing disease-modifying therapy (DMT) for multiple sclerosis (MS) appears to be a reasonable option for older patients with no relapses or MRI activity.

Switching or Discontinuing Disease-Modifying Therapies for MS

Circumstances might arise in which the patient or the physician considers the option of discontinuing DMT, but both should recognize the need for much more data ...

Discontinuation of disease-modifying therapies in multiple sclerosis

Stable disease course may prompt consideration of disease-modifying treatment (DMT) discontinuation in relapsing–remitting multiple sclerosis (RRMS). Objective:.